JPH0120880B2 - - Google Patents
Info
- Publication number
- JPH0120880B2 JPH0120880B2 JP9332780A JP9332780A JPH0120880B2 JP H0120880 B2 JPH0120880 B2 JP H0120880B2 JP 9332780 A JP9332780 A JP 9332780A JP 9332780 A JP9332780 A JP 9332780A JP H0120880 B2 JPH0120880 B2 JP H0120880B2
- Authority
- JP
- Japan
- Prior art keywords
- dione
- group
- hours
- general formula
- benzene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 claims description 22
- 238000000855 fermentation Methods 0.000 claims description 9
- 230000004151 fermentation Effects 0.000 claims description 9
- 241000223211 Curvularia lunata Species 0.000 claims description 8
- 241000223208 Curvularia Species 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 claims description 2
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 66
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 240000008042 Zea mays Species 0.000 description 11
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 11
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 11
- 235000005822 corn Nutrition 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 8
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 8
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000005273 aeration Methods 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 239000007836 KH2PO4 Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 4
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 4
- 235000019797 dipotassium phosphate Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 238000005805 hydroxylation reaction Methods 0.000 description 4
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 4
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 235000010344 sodium nitrate Nutrition 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000033444 hydroxylation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- JMBDKZWCKOAMDW-GQDVPIKJSA-N (8s,9s,10r,13s,14s,17s)-17-(2,2-dihydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)C(O)O)[C@@H]4[C@@H]3CCC2=C1 JMBDKZWCKOAMDW-GQDVPIKJSA-N 0.000 description 2
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 2
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- BEEBQIGKVOFYNO-KXSVHEDMSA-N (6S,8S,9S,10R,13S,14S,17S)-17-(2,2-dihydroxyacetyl)-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound OC(C([C@H]1CC[C@H]2[C@@H]3C[C@@H](C4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=O)C)=O)O BEEBQIGKVOFYNO-KXSVHEDMSA-N 0.000 description 1
- WNYLPFCKNQAAMB-PPUNREKOSA-N (8s,9s,10r,11s,13s,14s,16r,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O WNYLPFCKNQAAMB-PPUNREKOSA-N 0.000 description 1
- KOPMZTKUZCNGFY-UHFFFAOYSA-N 1,1,1-triethoxybutane Chemical compound CCCC(OCC)(OCC)OCC KOPMZTKUZCNGFY-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- KVUXYQHEESDGIJ-UHFFFAOYSA-N 10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,16-diol Chemical compound C1CC2CC(O)CCC2(C)C2C1C1CC(O)CC1(C)CC2 KVUXYQHEESDGIJ-UHFFFAOYSA-N 0.000 description 1
- JWMFYGXQPXQEEM-NUNROCCHSA-N 5β-pregnane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](CC)[C@@]2(C)CC1 JWMFYGXQPXQEEM-NUNROCCHSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001040638 Curvularia eragrostidis Species 0.000 description 1
- 150000000795 D-homosteroids Chemical class 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- WSVOMANDJDYYEY-CWNVBEKCSA-N prednylidene Chemical group O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WSVOMANDJDYYEY-CWNVBEKCSA-N 0.000 description 1
- 229960001917 prednylidene Drugs 0.000 description 1
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Description
【発明の詳細な説明】
本発明は一般式:
〔式中結合〓は単結合又は二重結合を表わし、X
は水素原子、弗素原子、塩素原子又はメチル基を
表わしかつVはメチレン基、エチレン基、エチリ
デン基又はビニリデン基を表わす〕の11β−ヒド
ロキシステロイドの製法に関し、これは一般式
:
〔式中〓、X及びVは前記のものを表わし、R1
は水素原子又は炭素原子1〜6個を有するアルキ
ル基を表わしかつR2は炭素原子1〜6個を有す
るアルキル基を表わす〕の11−デソキシステロイ
ドをクルブラリア(Curvularia)属の菌培地で醗
酵させることを特徴とする。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to the general formula: [Bond in the formula] represents a single bond or double bond,
represents a hydrogen atom, a fluorine atom, a chlorine atom, or a methyl group, and V represents a methylene group, an ethylene group, an ethylidene group, or a vinylidene group], which has the general formula: [In the formula], X and V represent the above, and R 1
represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and R 2 represents an alkyl group having 1 to 6 carbon atoms] is fermented in a bacterial culture of the genus Curvularia. It is characterized by causing
周知のように、抗炎作用を有する11β−ヒドロ
キシステロイド〔例えばコルチコイド;ヒドロコ
ルチゾン、プレドニゾロン、デキサメタゾン、ベ
タメタゾン、プレドニリデン又はフルランドレノ
ロン(Flurandrenolon)〕は非常に経費のかかる
多工程の部分合成により天然産生ステロイド(ジ
オスゲニン:Diosgenin)から製造される。 As is well known, 11β-hydroxysteroids (e.g. corticoids; hydrocortisone, prednisolone, dexamethasone, betamethasone, prednylidene or flurandrenolone) with anti-inflammatory effects can be produced naturally by a very expensive multi-step partial synthesis. Manufactured from a steroid (Diosgenin).
これらの化合物の多工程合成では一般にステロ
イド骨格中への11β−ヒドロキシ基を微生物学的
に導入することは経費の極めてかかるかつその際
に形成される副生成物のために非常に損失の多い
合成工程である。 In the multi-step synthesis of these compounds, the microbiological introduction of the 11β-hydroxy group into the steroid skeleton is generally a very expensive and very lossy synthesis due to the by-products formed. It is a process.
1966年に、プレグナン系の11−デソキシ−17α
−ヒドロキシステロイドを11β−ヒドロキシル化
する際に、17α−ヒドロキシ基をエステル化し、
クルブラリア属の菌を用いてヒドロキシル化しか
つ得られた11β−ヒドロキシ−17α−アシルオキ
システロイドをけん化することにより収率を著し
く高めることができる方法が開発された(西ドイ
ツ国特許第1618599号)。 In 1966, the pregnane 11-desoxy-17α
-When 11β-hydroxylating a hydroxysteroid, the 17α-hydroxy group is esterified,
A method has been developed which allows the yield to be significantly increased by hydroxylation using bacteria of the genus Curvularia and saponification of the resulting 11β-hydroxy-17α-acyloxysteroids (West German Patent No. 1618599).
この公知方法で出発化合物として使用される11
−デソキシ−17α−アシルオキシステロイドは周
知のように一般式の11−デソキシステロイドの
化学的加水分解により製造することができる。 11 used as starting compound in this known method
-Desoxy-17α-acyloxysteroids can be produced by chemical hydrolysis of 11-desoxysteroids of the general formula, as is well known.
この公知の3工程法に比べて本発明方法は、単
一工程法であるため経費は低くかつその方法によ
り方法生成物の高い収率が達成されるという利点
を有する。更に、本発明方法は意外にもしばしば
公知方法よりも著しく高い基質濃度と短い反応時
間で実施し得るという利点を有する。本発明方法
ではまた、しばしば全く困難である11β−ヒドロ
キシ−17α−アシルオキシステロイドの加水分解
をする必要はなく、この加水分解の際には殆んど
の場合副生成物が生じ、それ故多くの場合得られ
た生成物が医薬作用物質に必要な純度基準に相応
するように、経費がかかりかつ損失の多い生成物
の精製が必要である。 Compared to this known three-step process, the process according to the invention has the advantage that it is a single-step process, resulting in lower outlays and higher yields of the process product. Furthermore, the process according to the invention surprisingly often has the advantage that it can be carried out with significantly higher substrate concentrations and shorter reaction times than the known processes. The process of the invention also eliminates the need for hydrolysis of the 11β-hydroxy-17α-acyloxysteroids, which is often quite difficult; this hydrolysis almost always produces by-products and is therefore often In order for the product obtained to correspond to the purity standards required for pharmaceutical active substances, a complex and lossy purification of the product is necessary.
更に、本発明方法により非常に良好に一般式
の11β−ヒドロキシ−△1,4−ステロイドを一般式
の相応する11−デソキシ−△1,4−ステロイドか
ら製造することができるが、公知の技術水準では
11−デソキシ−△1,4−ステロイドを11β−位で良
好な収率でヒドロキシル化することはできないこ
とも注目に値する。 Furthermore, although the process according to the invention allows 11β-hydroxy-Δ 1,4 -steroids of the general formula to be produced very well from the corresponding 11-desoxy-Δ 1,4 -steroids of the general formula, the known techniques At the level
It is also noteworthy that 11-desoxy- Δ1,4 -steroids cannot be hydroxylated at the 11β-position with good yields.
最後に、本発明方法を実施するに当り、一般式
の11−デソキシステロイドを例えば次の方法で
精製生成物として製造する場合、出発化合物とし
てその精製物を使用する必要がないことが挙げら
れる:
ジメチルホルムアミド80ml及びベンゼン700ml
中のピリジニウムトシレート1g(40ミリモル)
及び17α,21−ジヒドロキシ−ステロイド10g
(28ミリモル)の溶液から痕跡量の水を除去する
ために浴温110〜130℃(グリセリン浴)で水分離
器の使用下にベンゼン300mlを留去させる。引続
いて短時間冷却し、オルトカルボン酸トリアルキ
ルエステル24ml(110〜140ミリモル)を添加しか
つ残りのベンゼンを1.5時間で留去させる。ピリ
ジン5.2mlの添加後、反応生成物を高度真空中で
濃度乾固させる。 Finally, in carrying out the process of the present invention, it is not necessary to use the purified product as a starting compound if the 11-desoxysteroid of the general formula is produced as a purified product, for example by the following method. : Dimethylformamide 80ml and benzene 700ml
1 g (40 mmol) of pyridinium tosylate in
and 10g of 17α,21-dihydroxy-steroid
300 ml of benzene are distilled off using a water separator at a bath temperature of 110-130 °C (glycerin bath) to remove traces of water from the solution of (28 mmol). This is followed by brief cooling, 24 ml (110-140 mmol) of orthocarboxylic acid trialkyl ester are added, and the remaining benzene is distilled off over 1.5 hours. After addition of 5.2 ml of pyridine, the reaction product is concentrated to dryness in a high vacuum.
反応は定量的に進行する。濃縮後残留する
17α,21−(1−アルコキシ−アルキリデンジオ
キシ)−ステロイドは初め油状コンシステンシー
を有するが、殆んどの場合短時間後には晶出す
る。純度は引続いて行なう微生物的ヒドロキシル
化に完全に十分であり、結晶に付着してゝも使用
反応成分の残分は酵素触媒作用を妨害しない。一
般式のD−ホモ−ステロイドも同様に製造す
る。 The reaction proceeds quantitatively. Remains after concentration
17α,21-(1-Alkoxy-alkylidenedioxy)-steroids initially have an oily consistency but in most cases crystallize after a short time. The purity is completely sufficient for the subsequent microbial hydroxylation, and any residues of the reaction components used, even if attached to the crystals, do not interfere with the enzyme catalysis. D-homo-steroids of the general formula are prepared in a similar manner.
ピリジニウムトシレートは次のように製造す
る:
P−トルエンスルホン酸・H2O54gを水分除
去のため十分な量のベンゼンで3回真空中で濃縮
乾固する。残渣にピリジン240mlを加え、1/2時間
後撹拌しかつ生成物をエーテルで析出させる。結
晶を吸引濾取し、エーテルで洗いかつ真空中50℃
で1時間乾燥させる。 Pyridinium tosylate is prepared as follows: 54 g of P-toluenesulfonic acid.H 2 O are concentrated to dryness in vacuo three times with sufficient benzene to remove water. 240 ml of pyridine are added to the residue, stirred after 1/2 hour and the product is precipitated with ether. The crystals were collected by suction filtration, washed with ether and incubated in vacuo at 50°C.
Let dry for 1 hour.
一般式の11−デソキシステロイドはアルキル
基R1及びR2とに炭素原子1〜6個を有する分枝
鎖状又は有利に直鎖状の基を有していてよい。例
えば好適なアルキル基R1及びR2はメチル基、エ
チル基、プロピル基、イソプロピル基、ブチル
基、ペンチル基及びヘキシル基である。特に優れ
ているアルキル基R1はメチル基である。特に優
れているアルキル基R2はメチル基及びエチレン
基である。 The 11-desoxysteroids of the general formula can have branched or preferably straight-chain radicals having 1 to 6 carbon atoms in the alkyl radicals R 1 and R 2 . For example, suitable alkyl groups R 1 and R 2 are methyl, ethyl, propyl, isopropyl, butyl, pentyl and hexyl. A particularly good alkyl group R 1 is the methyl group. Particularly preferred alkyl groups R 2 are the methyl group and the ethylene group.
6,7−位で飽和されている一般式の11−デ
ソキシステロイドでは殊に置換基Xはα−位であ
る。 In 11-desoxysteroids of the general formula which are saturated in the 6,7-position, the substituent X is in particular in the .alpha.-position.
一般式の11−デソキシステロイドをヒドロキ
シ化することができかつ一般式の相応する11β
−ヒドロキシステロイドに開裂することは当業者
にとつて驚異的である。本発明方法で所期の方法
生成物が非常に高い収率(理論量の約85〜90%)
で得られることを予測することはできなかつた。 11-desoxysteroids of the general formula can be hydroxylated and the corresponding 11β of the general formula
- cleavage to hydroxysteroids is surprising to the person skilled in the art. The method according to the invention provides very high yields of the desired process product (approx. 85-90% of theory)
I couldn't have predicted what I would get.
種々の出発化合物を使用することを除いて本発
明方法は、一般にクルブラリア菌属の菌によるス
テロイドの11β−ヒドロキシル化に適用される条
件下に実施する。 Except for the use of different starting compounds, the process of the invention is carried out under conditions generally applicable to the 11β-hydroxylation of steroids by fungi of the genus Curvularia.
例えば、ヒドロキシル化に好適なクルブラリア
属の菌はクルブラリア・フアルクタ(Curvularia
falcuta)QM−102H、クルブラリア・ゲンチク
ラタ(Curvularia genticulata)IFO(6284)、ク
ルブラリア・ルナタNRRL2380、NRRL2434、
NRRL2178、ATCC12017又はIFO(6286)もしく
はクルブラリア・マクランス(Curvularia
maculans)IFO(6292)である。 For example, a fungus of the genus Curvularia suitable for hydroxylation is Curvularia fulcta.
falcuta) QM-102H, Curvularia genticulata IFO (6284), Curvularia lunata NRRL2380, NRRL2434,
NRRL2178, ATCC12017 or IFO (6286) or Curvularia maculans
maculans) IFO (6292).
これらの微生物について一般式に適用されてい
る培養条件下に適当な培地中で通気下に深部培養
する。この培地に基質(適当な溶剤中に溶解する
か又は有利に乳化形で)を添加しかつ最高の基質
変換が達成されるまで醗酵させる。 These microorganisms are cultured submerged under aeration in a suitable medium under the culture conditions generally applicable. To this medium is added the substrate (dissolved in a suitable solvent or preferably in emulsified form) and fermented until the maximum substrate conversion is achieved.
例えば、好適な基質溶剤はメタノール、エタノ
ール、グリコールモノメチルエーテル、ジメチル
ホルムアミド又はジメチルスルホキシドである。
例えば、基質の乳化は、基質を微粉形で又は水と
混合可能な溶剤(例えばメタノール、エタノー
ル、アセトン、グリコールモノメチルエーテル、
ジメチルホルムアミド又はジメチルスルホキシ
ド)中に溶解して強力な乱流下に、常用の乳化助
剤を含有する水(有利には脱灰したもの)中に噴
射装入することにより行なうことができる。好適
な乳化助剤は例えばポリグリコールのエチレンオ
キシド付加物又は脂肪酸エステルのような非イオ
ン性乳化剤である。好適な乳化剤としては例えば
市販の湿潤剤テギン(Tegin(R))、タガート
(Tagat(R))、トイーン(Tween(R))及びシユパン
(Span(R))が挙げられる。 For example, suitable substrate solvents are methanol, ethanol, glycol monomethyl ether, dimethylformamide or dimethyl sulfoxide.
For example, emulsification of the substrate can be carried out in finely divided form or in water-miscible solvents such as methanol, ethanol, acetone, glycol monomethyl ether,
This can be carried out by injection into water (preferably demineralized) containing the customary emulsification aids under strong turbulence. Suitable emulsifying agents are nonionic emulsifiers, such as ethylene oxide adducts of polyglycols or fatty acid esters. Suitable emulsifiers include, for example, the commercially available wetting agents Tegin®, Tagat® , Tween® and Span® .
しばしば基質の乳化により高い基質処理量が可
能となり、従つて基質濃度の上昇が可能である。
しかし本発明方法では醗酵業者に周知である基質
処理量を高めるための他の方法を適用することも
勿論可能である。 Emulsification of the substrate often allows for high substrate throughputs and thus increases in substrate concentration.
However, it is of course possible to apply other methods for increasing the substrate throughput which are well known to fermenters in the method of the invention.
最適な基質濃度、基質供給時間及び醗酵時間は
使用する基質の構造及び使用する微生物の種類に
左右される。これらの程度については、微生物学
的ステロイド変換で一般に必要であるように、当
業者に周知である予備実験により個々の場合で確
定しなければならない。 The optimum substrate concentration, substrate feeding time and fermentation time depend on the structure of the substrate used and the type of microorganism used. These degrees must be determined in each individual case by preliminary experiments, which are well known to those skilled in the art, as is generally necessary in microbiological steroid conversions.
本発明方法により一般式の相応する11−デソ
キシステロイドから一般式を有する次の11β,
17α,21−トリヒドロキシ−4−プレグネン−
3,20−ジオン−誘導体を製造することができ
る:
11β,17α,21−トリヒドロキシ−4−プレグ
ネン−3,20−ジオン、
11β,17α,21−トリヒドロキシ−1,4−プ
レグナジエン−3,20−ジオン、
11β,17α,21−トリヒドロキシ−6α−メチル
−4−プレグネン−3,20−ジオン、
11β,17α,21−トリヒドロキシ−6α−メチル
−1,4−プレグナジエン−3,20−ジオン、
11β,17α,21−トリヒドロキシ−6−クロル
−4,6−プレグナジエン−3,20−ジオン、
11β,17α,21−トリヒドロキシ−6−クロル
−1,4,6−プレグナトリエン−3,20−ジオ
ン、
11β,17α,21−トリヒドロキシ−16α−メチル
−4−プレグネン−3,20−ジオン、
11β,17α,21−トリヒドロキシ−16α−メチル
−1,4−プレグナジエン−3,20−ジオン、
11β,17α,21−トリヒドロキシ−16β−メチル
−4−プレグネン−3,20−ジオン、
11β,17α,21−トリヒドロキシ−16β−メチル
−1,4−プレグナジエン−3,20−ジオン、
11β,17α,21−トリヒドロキシ−16−メチル
−4−プレグネン−3,20−ジオン、
11β,17α,21−トリヒドロキシ−16−メチレ
ン−1,4−プレグナジエン−3,20−ジオン、
11β,17α,21−トリヒドロキシ−D−ホモ−
4−プレグネン−3,20−ジオン、
11β,17α,21−トリヒドロキシ−D−ホモ−
1,4−プレグナジエン−3,20−ジオン、
6α−フルオル−11β,17α,21−トリヒドロキ
シ−4−プレグネン−3,20−ジオン、
6α−フルオル−11β,17α,21−トリヒドロキ
シ−1,4−プレグナジエン−3,20−ジオン。 By the method of the present invention, the following 11β having the general formula is obtained from the corresponding 11-desoxysteroid of the general formula:
17α,21-trihydroxy-4-pregnene-
3,20-dione derivatives can be prepared: 11β,17α,21-trihydroxy-4-pregnene-3,20-dione, 11β,17α,21-trihydroxy-1,4-pregnadiene-3, 20-dione, 11β,17α,21-trihydroxy-6α-methyl-4-pregnene-3,20-dione, 11β,17α,21-trihydroxy-6α-methyl-1,4-pregnadiene-3,20- dione, 11β,17α,21-trihydroxy-6-chloro-4,6-pregnadiene-3,20-dione, 11β,17α,21-trihydroxy-6-chloro-1,4,6-pregnatriene-3, 20-dione, 11β,17α,21-trihydroxy-16α-methyl-4-pregnene-3,20-dione, 11β,17α,21-trihydroxy-16α-methyl-1,4-pregnadiene-3,20- dione, 11β,17α,21-trihydroxy-16β-methyl-4-pregnene-3,20-dione, 11β,17α,21-trihydroxy-16β-methyl-1,4-pregnadiene-3,20-dione, 11β,17α,21-trihydroxy-16-methyl-4-pregnene-3,20-dione, 11β,17α,21-trihydroxy-16-methylene-1,4-pregnadiene-3,20-dione, 11β, 17α,21-trihydroxy-D-homo-
4-pregnene-3,20-dione, 11β,17α,21-trihydroxy-D-homo-
1,4-pregnadiene-3,20-dione, 6α-fluoro-11β,17α,21-trihydroxy-4-pregnene-3,20-dione, 6α-fluoro-11β,17α,21-trihydroxy-1, 4-Pregnadiene-3,20-dione.
次に本発明方法を実施例につき詳説する。 Next, the method of the present invention will be explained in detail with reference to examples.
例 1
(a) ピリジニウムトシレート8g及び17α,21−
ジヒドロキシ−4−プレグネン−3,20−ジオ
ン80gをジメチルホルムアミド560ml中に溶か
しかつベンゼン3.5で稀釈する。その後、水
分離器を介して浴温120℃でベンゼン1.5を留
去する。熱い反応溶液中に徐々にオルト酢酸ト
リエチルエステル192mlを流入させ、引続いて
1時間ベンゼン及び他の易揮発性反応成分を留
去する。ピリジン96mlを加えかつ浴温60℃で高
度真空中2時間で完全に濃縮乾固する。初め油
状である残渣が迅速に晶出する。17α,21−
(1−エトキシ−エチリデンジオキシ)−4−プ
レグネン−3,20−ジオン113gが融点89〜90
℃の黄色結晶形で得られる。Example 1 (a) 8 g of pyridinium tosylate and 17α,21−
80 g of dihydroxy-4-pregnene-3,20-dione are dissolved in 560 ml of dimethylformamide and diluted with 3.5 g of benzene. Thereafter, 1.5 benzene is distilled off via a water separator at a bath temperature of 120°C. 192 ml of orthoacetic acid triethyl ester are gradually introduced into the hot reaction solution, followed by distillation of benzene and other easily volatile reaction components for 1 hour. Add 96 ml of pyridine and concentrate completely to dryness in a high vacuum for 2 hours at a bath temperature of 60°C. The initially oily residue quickly crystallizes out. 17α, 21−
113 g of (1-ethoxy-ethylidenedioxy)-4-pregnene-3,20-dione has a melting point of 89-90.
Obtained in yellow crystalline form at °C.
(b) オートクレーブ中120℃で30分間滅菌した、
グルコース3%、コーン・スチープ1%、
NaNO30.2%、KH2PO40.1%、K2HPO40.2%、
MgSO4・7H2O0.05%、FeSO4・7H2O0.002%
及びKCl0.05%から成る培養液500mlを含有す
る2−三角フラスコにクルブラリア・ルナタ
(NRRL)の凍結乾燥培養物を接種し、回転振
盪機上で30℃60時間動かす。この培養物(250
ml)を、グルコース2%及びコーン・スチープ
2%より成り、PH6.5に調節し、121℃及び
1.1atu¨で滅菌した培地15が装入されている20
−予備醗酵槽への接種に使用する。抑泡剤と
してシリコンSHの添加下に29℃及び圧力
0.7atu¨で通気(10/分)及び撹拌(220r.p.
m.)下に24時間発芽させる。その後この培地
の1.5を無菌条件下に取り、それを、コー
ン・スチープ3%及びグルコース0.7%より成
り、PH6.5に調節した上記のように滅菌した培
地14が装入されている20−主醗酵槽に接種
する。予備醗酵槽の条件下に12時間の生長時間
後に、ジメチルホルムアミド100ml中に溶解し
た粗製17α,21−(1−エトキシ−エチリデン
ジオキシ)−4−プレグネン−3,20−ジオン
7.5g(純物質6.43gを含有する)を滅菌条件
下に添加しかつ更に撹拌しかつ通気する。醗酵
の経過は試料を取り出し、メチルイソブチルケ
トンで抽出しかつ薄層クロマトグラフイーによ
り分析して検査する。接触時間38時間後に基質
の変換は終結する。(b) sterilized in an autoclave at 120°C for 30 min;
Glucose 3%, Corn Steep 1%,
NaNO3 0.2%, KH2PO4 0.1 %, K2HPO4 0.2 %,
MgSO4・7H2O0.05 %, FeSO4・7H2O0.002 %
A 2-erlenmeyer flask containing 500 ml of a culture medium consisting of C. and 0.05% KCl is inoculated with a freeze-dried culture of Curvularia lunata (NRRL) and moved on a rotary shaker at 30° C. for 60 hours. This culture (250
ml) consisting of 2% glucose and 2% corn steep, adjusted to pH 6.5, heated at 121°C and
1.1Atu¨ sterilized medium 15 is charged 20
- Used to inoculate prefermenters. 29℃ and pressure with addition of silicone SH as foam suppressant
Aeration (10/min) and stirring (220 r.p. at 0.7 atu¨)
m.) Allow to germinate under 24 hours. 1.5 of this medium was then taken under sterile conditions and charged with medium 14, sterilized as above, consisting of 3% corn steep and 0.7% glucose, and adjusted to a pH of 6.5. Inoculate the fermenter. Crude 17α,21-(1-ethoxy-ethylidenedioxy)-4-pregnene-3,20-dione dissolved in 100 ml of dimethylformamide after a growth period of 12 hours under prefermenter conditions.
7.5 g (containing 6.43 g of pure material) are added under sterile conditions and further stirred and vented. The progress of the fermentation is checked by taking samples, extracting them with methyl isobutyl ketone and analyzing them by thin layer chromatography. Conversion of the substrate is complete after a contact time of 38 hours.
醗酵槽内容物を濾過し、培養物濾液かつまた
濾別したミセルをメチルイソブチルケトンで抽
出し、抽出物を合しかつ初めに還流式蒸発器中
で濃縮し、次いで回転式蒸発器中で真空中浴温
50℃で濃縮乾固する。残渣を加温したメタノー
ル中に溶かし、不溶残留シリコン油を濾別しか
つ再度蒸発乾固する。残渣(9.4g)を酢酸エ
チルエステル40ml中に熱時に溶解し、初め室温
で、次いで低温静置時に結晶させる。結晶生成
物を吸引濾取し、少量の冷い酢酸エステルで洗
浄しかつ真空乾燥箱中60℃で5時間乾燥させ
る。融点212〜214℃のヒドロコルチゾン
(11β,17α,21−トリヒドロキシ−4−プレグ
ネン−3,20−ジオン)4.18gが得られる。結
晶母液を活性炭と一緒に加熱し、濾過しかつ容
積15mlに濃縮する。冷却しかつ室温で一晩放置
する際に更に融点208〜210℃のヒドロコルチゾ
ン0.7gが結晶する。従つて全収率は理論量の
87.1%である。 The fermenter contents were filtered, the culture filtrate and also the filtered micelles were extracted with methyl isobutyl ketone, the extracts were combined and concentrated first in a reflux evaporator and then in a rotary evaporator under vacuum. Medium bath temperature
Concentrate to dryness at 50℃. The residue is dissolved in warm methanol, the undissolved residual silicone oil is filtered off and evaporated again to dryness. The residue (9.4 g) is dissolved hot in 40 ml of ethyl acetate and crystallized first at room temperature and then on standing at low temperature. The crystalline product is filtered off with suction, washed with a small amount of cold acetate and dried for 5 hours at 60° C. in a vacuum drying box. 4.18 g of hydrocortisone (11β,17α,21-trihydroxy-4-pregnene-3,20-dione) with a melting point of 212-214°C are obtained. The crystal mother liquor is heated with activated charcoal, filtered and concentrated to a volume of 15 ml. Upon cooling and standing overnight at room temperature, a further 0.7 g of hydrocortisone with a melting point of 208 DEG-210 DEG C. crystallizes. Therefore, the total yield is the theoretical amount
It is 87.1%.
例 2
(a) ピリジニウムトシレート7g及び17α,21−
ジヒドロキシ−4−プレグネン−3,20−ジオ
ン70gをジメチルホルムアミド560ml中に溶解
しかつベンゼン4.9で稀釈する。溶温130℃で
水分離器を介してベンゼン2.1を留去しかつ
短時間の冷却後オルト酪酸トリエチルエステル
168mlを加える。130℃、1.5時間で残りのベン
ゼンを留去する。この溶液にピリジン84mlを加
えかつ引続いて回転式蒸発器を用いて高度真空
中で濃縮乾固する。17α,21−(1−エトキシ
−ブチリデンジオキシ)−4−プレグネン−3,
20−ジオン103.8gが油状物として得られる。Example 2 (a) 7 g of pyridinium tosylate and 17α,21−
70 g of dihydroxy-4-pregnene-3,20-dione are dissolved in 560 ml of dimethylformamide and diluted with 4.9 g of benzene. Orthobutyric acid triethyl ester after distilling off benzene 2.1 through a water separator at a melt temperature of 130°C and after short cooling.
Add 168ml. The remaining benzene is distilled off at 130°C for 1.5 hours. 84 ml of pyridine are added to this solution and it is subsequently concentrated to dryness in a high vacuum using a rotary evaporator. 17α,21-(1-ethoxy-butylidenedioxy)-4-pregnene-3,
103.8 g of 20-dione are obtained as an oil.
(b) 例1(b)の条件下に純物質6.3gを含有する粗
製の17α,21−(1−エトキシ−ブチリデンジ
オキシ)−4−プレグネン−3,20−ジオン7.5
gをクルブラリア・ルナタ培地により47時間醗
酵させる。バツチを後処理しかつシリコンを含
まない抽出残渣を酢酸エチルエステルから結晶
させた後で合計してヒドロコルチゾン(融点
210〜213℃)4.3gが得られる。(b) 7.5 g of crude 17α,21-(1-ethoxy-butylidenedioxy)-4-pregnene-3,20-dione containing 6.3 g of pure material under the conditions of Example 1(b).
g was fermented for 47 hours in Curvularia lunata medium. Hydrocortisone (melting point
210-213°C) 4.3g is obtained.
例 3
(a) ピリジニウムトシレート5.3g及び17α,21−
ジヒドロキシ−6α−メチル−4−プレグネン
−3,20−ジオン53gをジメチルホルムアミド
370ml中に溶解しかつベンゼン2.5で稀釈す
る。その後、浴温130℃で水分離器を介してベ
ンゼン1を留去する。熱い反応溶液中にオル
ト酢酸エチルエステル127mlを徐々に流入し、
次いでベンゼン及び他の易揮発性反応成分を1
時間留去させる。ピリジン63mlを添加しかつ高
度真空中、浴温60℃及び2時間で完全に濃縮乾
固する。油状の17α,21−(1−エトキシ−エ
チリデンジオキシ)−6α−メチル−4−プレグ
ネン−3,20−ジオン66.8gが得られる。Example 3 (a) 5.3 g of pyridinium tosylate and 17α,21−
53 g of dihydroxy-6α-methyl-4-pregnene-3,20-dione was dissolved in dimethylformamide.
Dissolve in 370 ml and dilute with benzene 2.5. Thereafter, benzene 1 is distilled off via a water separator at a bath temperature of 130°C. Gradually pour 127 ml of orthoacetic acid ethyl ester into the hot reaction solution.
Benzene and other easily volatile reactants are then added to 1
Allow time to evaporate. 63 ml of pyridine are added and the mixture is completely concentrated to dryness in a high vacuum at a bath temperature of 60° C. for 2 hours. 66.8 g of oily 17α,21-(1-ethoxy-ethylidenedioxy)-6α-methyl-4-pregnene-3,20-dione are obtained.
油状残渣の試料を蒸留水と激しく撹拌する
と、油状物は徐々に結晶状に変化する。融点
75/92〜95℃。 When a sample of the oily residue is vigorously stirred with distilled water, the oil gradually turns crystalline. melting point
75/92~95℃.
(b) 例1(b)の条件下に純物質4.8gを含有する粗
製の17α,21−(1−エトキシ−エチリデンジ
オキシ)−6α−メチル−4−プレグネン−3,
20−ジオン6gをクルブラリア・ルナタ培地で
51時間醗酵させる。バツチを後処理しかつ抽出
残渣をジイソプロピルエーテルから結晶させた
後で融点217〜219℃の6α−メチル−ヒドロキ
シコルチゾン3.4gが得られる。(b) Crude 17α,21-(1-ethoxy-ethylidenedioxy)-6α-methyl-4-pregnene-3, containing 4.8 g of pure material under the conditions of Example 1(b).
20-6 g of dione in Curvularia lunata medium
Ferment for 51 hours. After working up the batch and crystallizing the extraction residue from diisopropyl ether, 3.4 g of 6α-methyl-hydroxycortisone are obtained, melting point 217-219°C.
例 4
(a) ピリジニウムトシレート4g及び17α,21−
ジヒドロキシ−1,4−プレグナジエン−3,
20−ジオン40gをジメチルホルムアミド280ml
中に溶かしかつベンゼン2で稀釈する。その
後、浴温120℃で水分離器を介してベンゼン600
mlを留去する。この熱い反応溶液中にオルト酢
酸トリエチルエステル96mlを徐々に流入させ、
次いで更にベンゼン及び他の易揮発性反応成分
を留去させる。ピリジン48mlを添加しかつ高度
真空中浴温60℃、2時間で完全に濃縮乾固す
る。17α,21−(1−エトキシ−エチリデンジ
オキシ)−1,4−プレグナジエン−3,20−
ジオン58gが帯黄色結晶として得られる。試料
を、活性炭で処理後アセトン1%を含むエーテ
ルから再結晶させかつ融点153〜154℃の純粋な
生成物を得る。Example 4 (a) 4 g of pyridinium tosylate and 17α,21−
dihydroxy-1,4-pregnadiene-3,
20-40g of dione and 280ml of dimethylformamide
and diluted with 2 parts of benzene. Then benzene 600 ml via water separator with bath temperature 120℃
ml is distilled off. 96 ml of orthoacetic acid triethyl ester was gradually introduced into the hot reaction solution.
Benzene and other easily volatile reaction components are then further distilled off. Add 48 ml of pyridine and completely concentrate to dryness in a high vacuum at a bath temperature of 60°C for 2 hours. 17α,21-(1-ethoxy-ethylidenedioxy)-1,4-pregnadiene-3,20-
58 g of dione are obtained as yellowish crystals. The sample is recrystallized from ether containing 1% acetone after treatment with activated charcoal and a pure product with a melting point of 153 DEG-154 DEG C. is obtained.
(b) グリコース3%、コーン・スチープ1%、
NaNO30.2%、KH2PO40.1%、K2HPO40.2%、
MgSO4・7H2O0.05%、FeSO4・7H2O0.002%
及びKCl0.05%より成り、オートクレーブ中
120℃で30分間滅菌した培養液500mlを含有する
2−三角フラスコにクルブラリア・ルナタ
(NRRL2380)の凍結乾燥培地を接種しかつ回
転振盪機上30℃で60時間動かす。この培養物
を、グルコース2%及びコーン・スチープ2%
より成りかつPH6.5に調節した121℃及び1.1atu¨
で滅菌した培地15が装入されている20−予
備醗酵槽の接種に使用する。抑泡剤としてシリ
コンSHの添加下に29℃及び圧力0.7atu¨で通気
(10/分)及び撹拌(220r.p.m.)下に24時間
発芽させる。その後、この培養物1.5を滅菌
条件下に取りかつそれを、コーン・スチープ3
%及びグルコース0.7%より成り、PH5.5に調節
した前記のように滅菌した培地14を装入した
20−主醗酵槽に接種する。(b) 3% glycose, 1% corn steep;
NaNO3 0.2%, KH2PO4 0.1 %, K2HPO4 0.2 %,
MgSO4・7H2O0.05 %, FeSO4・7H2O0.002 %
and KCl 0.05%, in autoclave
A 2-erlenmeyer flask containing 500 ml of culture sterilized for 30 minutes at 120°C is inoculated with freeze-dried medium of Curvularia lunata (NRRL 2380) and run for 60 hours at 30°C on a rotary shaker. This culture was mixed with 2% glucose and 2% corn steep.
121℃ and 1.1atu¨ and adjusted to PH6.5
20 - Used to inoculate the pre-fermenter, which is charged with medium 15 sterilized by . Germinate for 24 hours under aeration (10/min) and stirring (220 r.pm) at 29° C. and a pressure of 0.7 atu¨ with the addition of silicone SH as a foam suppressant. Thereafter, take 1.5 of this culture under sterile conditions and transfer it to a cone steeper.
% and glucose 0.7%, sterilized as above and adjusted to pH 5.5.
20- Inoculate the main fermenter.
予備醗酵槽の条件下に12時間の生長時間後に
ジメチルホルムアミド100ml中に溶解した17α,
21−(1−エトキシ−エチリデンジオキシ)−
1,4−プレグナジエン−3,20−ジオン7.5
gを無菌条件下に添加し、更に撹拌し通気す
る。醗酵の経過は試料を採取することにより検
査するが、試料をメチルイソブチルケトンで抽
出しかつ薄層クロマトグラフイーにより分析す
る。接触時間36時間後に基質の変換は終結す
る。醗酵槽の内容物を濾過し、培養物濾液及び
濾別したミセルをメチルイソブチルケトンで抽
出し、抽出液を一緒にし、初めに還流式蒸発器
中で濃縮し、次いで回転式蒸発器中で真空中浴
温50℃で100mlに濃縮しかつ室温で結晶させる。
生成物を吸引濾取し、真空中で乾燥させ、融点
229〜231℃のプレドニゾロン5.7gを得る。 17α, dissolved in 100 ml of dimethylformamide after a growth period of 12 hours under prefermenter conditions.
21-(1-ethoxy-ethylidenedioxy)-
1,4-pregnadiene-3,20-dione 7.5
g under aseptic conditions and further stirred and aerated. The progress of the fermentation is checked by taking samples, which are extracted with methyl isobutyl ketone and analyzed by thin layer chromatography. Conversion of the substrate is complete after a contact time of 36 hours. The contents of the fermenter were filtered, the culture filtrate and the filtered micelles were extracted with methyl isobutyl ketone, the extracts were combined and concentrated first in a reflux evaporator and then in a rotary evaporator under vacuum. Concentrate to 100 ml at a medium bath temperature of 50°C and crystallize at room temperature.
The product was filtered off with suction and dried in vacuo, melting point
Obtain 5.7 g of prednisolone at 229-231°C.
例 5
(a) ピリジニウムトシレート0.62g及びD−ホモ
−ライヒシユタインS6.2gをジメチルホルムア
ミド43.4ml中に溶解しかつベンゼン270mlで稀
釈する。その後水分離器を介して浴温120℃で
ベンゼン116mlを留去させる。この熱い反応溶
液中にオルト酢酸トリメチルエステル14.9mlを
徐々に流入させかつ次いでベンゼンと他の易揮
発性反応成分を1時間留去させる。ピリジン
7.5mlを添加しかつ高度真空中浴温60℃で2時
間で完全に濃縮乾固する。17,21−(1−メト
キシ−エチリデンジオキシ)−D−ホモ−4−
プレグネン−3,20−ジオン7.3gが融点167〜
169℃の黄色結晶形で得られる。Example 5 (a) 0.62 g of pyridinium tosylate and 6.2 g of D-homo-Reichscheutain S are dissolved in 43.4 ml of dimethylformamide and diluted with 270 ml of benzene. Thereafter, 116 ml of benzene is distilled off via a water separator at a bath temperature of 120°C. 14.9 ml of orthoacetic acid trimethyl ester are slowly introduced into the hot reaction solution and the benzene and other easily volatile reaction components are then distilled off for 1 hour. pyridine
Add 7.5 ml and completely concentrate to dryness in a high vacuum at a bath temperature of 60°C for 2 hours. 17,21-(1-methoxy-ethylidenedioxy)-D-homo-4-
7.3g of pregnene-3,20-dione has a melting point of 167~
Obtained in yellow crystalline form at 169°C.
(b) グルコース3%、コーン・スチープ1%、
NaNO30.02%、KH2PO40.1%、K2HPO40.2
%、MgSO4・7H2O0.05%、FeSO4・
7H2O0.002%及びKCl0.05%より成る、オート
クレーブ中120℃で30分間滅菌した培養液500ml
を含有する2−三角フラスコにクルブラリ
ア・ルナタ(NRRL2380)の凍結乾燥培養物
を接種しかつ回転振盪機上30℃で60時間動か
す。この培養物(250ml)を、グルコース2%
及びコーン・スチープ2%より成り、PH6.5に
調節した120℃及び1.1atu¨で滅菌した培地15
が装入されている20−予備醗酵槽の接種に使
用する。抑泡剤としてシリコンSHの添加下に
29℃及び圧力0.7atu¨で通気(10/分)及び撹
拌(220r.p.m.)下に24時間発芽させる。その
後、この培養物1.5を無菌条件下に採取しか
つそれを、コーン・スチープ3%及びグルコー
ス0.7%より成りかつPH6.5に調節した前記のよ
うに滅菌した培地14を装入した20−主醗酵
槽に接種する。予備醗酵の条件下に生長時間12
時間後にジメチルホルムアミド100ml中に溶解
した17,21−(1−メトキシ−エチリデンジオ
キシ)−D−ホモ−4−プレグネン−3,20−
ジオン7.3gを無菌条件下に添加し、更に撹拌
しかつ通気する。醗酵の経過は試料の採取によ
り検査するが、試料をメチルイソブチルケトン
で抽出しかつ薄層クロマトグラフイーにより分
析する。48時間の接触時間後に基質の変換は終
結する。(b) 3% glucose, 1% corn steep;
NaNO3 0.02%, KH2PO4 0.1 %, K2HPO4 0.2
%, MgSO4・7H2O0.05 %, FeSO4・
500 ml of culture solution consisting of 0.002% 7H 2 O and 0.05% KCl, sterilized in an autoclave at 120°C for 30 minutes.
A 2-erlenmeyer flask containing a 2-erlenmeyer flask was inoculated with a lyophilized culture of Curvularia lunata (NRRL 2380) and run for 60 hours at 30°C on a rotary shaker. This culture (250 ml) was added to 2% glucose
and corn steep 2%, sterilized at 120°C and 1.1 atu¨ and adjusted to pH 6.515
20 - Used to inoculate the pre-fermenter. With the addition of silicone SH as a foam suppressor
Germinate for 24 hours at 29° C. and pressure 0.7 atu¨ under aeration (10/min) and stirring (220 r.pm). This culture 1.5 was then harvested under sterile conditions and placed in a medium 14 sterilized as described above consisting of 3% corn steep and 0.7% glucose and adjusted to a pH of 6.5. Inoculate the fermenter. Growth time 12 under conditions of pre-fermentation
17,21-(1-methoxy-ethylidenedioxy)-D-homo-4-pregnene-3,20- dissolved in 100 ml of dimethylformamide after hours.
7.3 g of dione are added under aseptic conditions, followed by stirring and aeration. The progress of the fermentation is checked by taking samples, which are extracted with methyl isobutyl ketone and analyzed by thin layer chromatography. Conversion of the substrate is complete after a contact time of 48 hours.
醗酵内容物を濾過し、培養物濾液及び濾別し
たミセルをメチルイソブチルケトンで抽出し、
抽出物を−緒にしかつ初め還流式蒸発器で濃縮
し、次いで回転式蒸発器において真空中浴温50
℃で濃縮乾固する。残渣を熱いメタノール中に
溶かし、不溶残留シリコン油を濾別しかつ再度
濃縮乾固する。残分を珪酸ゲルカラム(傾斜塩
化メチレン4.5/アセトン0.5〜塩化メチレ
ン4/アセトン1)を介してクロマトグラ
フイー処理しかつアセトンから結晶させる。融
点212〜215℃(分解)のD−ホモ−ヒドロコル
チゾン(11β,17α,21−トリヒドロキシ−D
−ホモ−4−プレグネン−3,20−ジオン)
5.7gが得られる。 Filter the fermentation contents, extract the culture filtrate and filtered micelles with methyl isobutyl ketone,
The extracts were combined and concentrated first in a reflux evaporator and then in a rotary evaporator in vacuo at a bath temperature of 50°C.
Concentrate to dryness at °C. The residue is dissolved in hot methanol, the undissolved residual silicone oil is filtered off and concentrated again to dryness. The residue is chromatographed on a silicic acid gel column (gradient 4.5 methylene chloride/0.5 acetone to 4 methylene chloride/1 acetone) and crystallized from acetone. D-homo-hydrocortisone (11β, 17α, 21-trihydroxy-D
-homo-4-pregnene-3,20-dione)
5.7g is obtained.
例 6
(a) ピリジニウムトシレート1.5g及び17α,21−
ジヒドロキシ−D−ホモ−1,4−プレグナジ
エン−3,20−ジオン15gをジメチルホルムア
ミド120ml中に溶解しかつベンゼン800mlで稀釈
する。その後、水分離器を介して浴温120℃で
ベンゼン250mlを留去させる。この熱い反応溶
液中にオルト酢酸トリメチルエステル40mlを
徐々に流入させかつ次いで更にベンゼン及び他
の易揮発性反応成分を留去させる。ピリジン20
mlを添加し、高度真空中浴温60℃で2時間で完
全に濃縮乾固する。油状の結晶粗製物18.8gが
残留する。試料を活性炭で処理後イソプロピル
エーテルから再結晶させる。融点142〜144℃の
純粋な17α,21−(1−メトキシ−エチリデン
ジオキシ)−D−ホモ−1,4−プレグナジエ
ン−3,20−ジオンが得られる。Example 6 (a) 1.5 g of pyridinium tosylate and 17α,21−
15 g of dihydroxy-D-homo-1,4-pregnadiene-3,20-dione are dissolved in 120 ml of dimethylformamide and diluted with 800 ml of benzene. Thereafter, 250 ml of benzene is distilled off via a water separator at a bath temperature of 120°C. 40 ml of orthoacetic acid trimethyl ester are slowly introduced into the hot reaction solution and the benzene and other easily volatile reaction components are then further distilled off. pyridine 20
ml and completely concentrated to dryness in a high vacuum at a bath temperature of 60°C for 2 hours. 18.8 g of oily crystalline crude remain. The sample is treated with activated carbon and then recrystallized from isopropyl ether. Pure 17α,21-(1-methoxy-ethylidenedioxy)-D-homo-1,4-pregnadiene-3,20-dione is obtained with a melting point of 142 DEG -144 DEG C.
(b) グルコース3%、コーン・スチープ1%、
NaNO30.2%、KH2PO40.1%、K2HPO40.2%、
MgSO4・7H2O0.05%、FeSO4・7H2O0.002%
及びKCl0.05%より成り、オートクレーブ中
120℃で30分間滅菌した培養液500mlを含有する
2−三角フラスコにクルブラリア・ルナタ
(NRRL2380)の凍結乾燥培養物を接種しかつ
回転振盪機上30℃で60時間動かす。この培養物
(250ml)を、グルコース2%及びコーン・スチ
ープ2%より成り、PH6.5に調節した121℃及び
1.1atu¨で滅菌した培地15で装入されている20
−予備醗酵槽の接種に使用する。抑泡剤とし
てシリコンSHの添加下に29℃及び圧力0.7atu¨
で通気(10/分)及び撹拌(220r.p.m.)下
に24時間発芽させる。その後、この培養物の
1.5を無菌条件下に採取しかつそれを、コー
ン・スープ3%及びグルコース0.7%より成り、
PH5.5に調節した前記のように滅菌した培地14
が装入されている20−主醗酵槽に接種す
る。(b) 3% glucose, 1% corn steep;
NaNO3 0.2%, KH2PO4 0.1 %, K2HPO4 0.2 %,
MgSO4・7H2O0.05 %, FeSO4・7H2O0.002 %
and KCl 0.05%, in autoclave
A 2-erlenmeyer flask containing 500 ml of culture sterilized for 30 minutes at 120°C is inoculated with a lyophilized culture of Curvularia lunata (NRRL 2380) and run on a rotary shaker for 60 hours at 30°C. This culture (250 ml) was incubated at 121° C. with 2% glucose and 2% corn steep and adjusted to pH 6.5.
1.1Atu¨20 is charged with sterilized medium 15
- Used for inoculating prefermenters. 29℃ and pressure 0.7atu¨ with addition of silicone SH as foam suppressant
Germinate for 24 hours under aeration (10/min) and stirring (220 rpm). Then, this culture
1.5 was collected under sterile conditions and made up of 3% corn soup and 0.7% glucose;
Medium 14 sterilized as above and adjusted to pH 5.5
Inoculate the 20-main fermentor that is charged with.
予備醗酵条件下に12時間の生長時間後に、ジ
メチルホルムアミド100ml中に溶かした17α,
21−(1−メトキシ−エチリデンジオキシ)−D
−ホモ−1,4−プレグナジエン−3,20−ジ
オン7.5gを滅菌条件下に添加し、更に撹拌し
かつ通気する。醗酵の経過は試料を採取するこ
とにより検査するが、この試料をメチルイソブ
チルケトンで抽出しかつ薄層クロマトグラフイ
ーにより分析する。接触時間52時間後、基質の
変換は終結する。醗酵槽内容物を濾過し、培養
物濾液及び濾別したミセルをメチルイソブチル
ケトンで抽出し、抽出物を一緒にしかつ初めに
還流式蒸発器中で濃縮し、次いで回転式蒸発器
において真空中浴温50℃で100mlに濃縮しかつ
室温で結晶させる。生成物を吸引濾取しかつ真
空中で乾燥させる。融点226〜228℃のD−ホモ
−プレドニゾロン(11β,17α,21−トリヒド
ロキシ−D−ホモ−1,4−プレグナジエン−
3,20−ジオン)6.1gが得られる。 17α, dissolved in 100 ml of dimethylformamide after a growth period of 12 hours under pre-fermentation conditions.
21-(1-methoxy-ethylidenedioxy)-D
7.5 g of homo-1,4-pregnadiene-3,20-dione are added under sterile conditions, followed by stirring and aeration. The progress of the fermentation is checked by taking samples, which are extracted with methyl isobutyl ketone and analyzed by thin layer chromatography. After a contact time of 52 hours, the conversion of the substrate is complete. The fermenter contents were filtered, the culture filtrate and the filtered micelles were extracted with methyl isobutyl ketone, the extracts were combined and concentrated first in a reflux evaporator and then in a vacuum bath in a rotary evaporator. Concentrate to 100 ml at 50°C and crystallize at room temperature. The product is filtered off with suction and dried in vacuo. D-homo-prednisolone (11β,17α,21-trihydroxy-D-homo-1,4-pregnadiene-
6.1 g of 3,20-dione) are obtained.
Claims (1)
は水素原子、弗素原子、塩素原子又はメチル基を
表わしかつVはメチレン基、エチレン基、エチリ
デン基又はビニリデン基を表わす〕の11β−ヒド
ロキシステロイドを製造する方法において、一般
式: 〔式中〓、X及びVは前記のものを表わし、R1
は水素原子又は炭素原子1〜6個を有するアルキ
ル基を表わしかつR2は炭素原子1〜6個を有す
るアルキル基を表わす〕の11−デソキシステロイ
ドをクルブラリア属の菌培地で醗酵させることを
特徴とする11β−ヒドロキシステロイドの製法。 2 醗酵をクルブラリア・ルナタ種の菌培地で行
なう特許請求の範囲第1項記載の製法。 3 一般式を有する11β−ヒドロキシ−D−ホ
モ−ステロイドを製造する特許請求の範囲第1又
は第2項記載の製法。[Claims] 1. General formula: [Bond in the formula] represents a single bond or double bond,
represents a hydrogen atom, a fluorine atom, a chlorine atom, or a methyl group, and V represents a methylene group, an ethylene group, an ethylidene group, or a vinylidene group], the general formula: [In the formula], X and V represent the above, and R 1
represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and R 2 represents an alkyl group having 1 to 6 carbon atoms] is fermented in a culture medium of Curvularia spp. Characteristic method for producing 11β-hydroxysteroids. 2. The production method according to claim 1, wherein the fermentation is carried out in a culture medium of Curvularia lunata species. 3. The method according to claim 1 or 2 for producing a 11β-hydroxy-D-homo-steroid having the general formula.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9332780A JPS5729295A (en) | 1980-07-10 | 1980-07-10 | Production of 11 beta-hydroxysteroid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9332780A JPS5729295A (en) | 1980-07-10 | 1980-07-10 | Production of 11 beta-hydroxysteroid |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5729295A JPS5729295A (en) | 1982-02-17 |
JPH0120880B2 true JPH0120880B2 (en) | 1989-04-18 |
Family
ID=14079173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9332780A Granted JPS5729295A (en) | 1980-07-10 | 1980-07-10 | Production of 11 beta-hydroxysteroid |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5729295A (en) |
-
1980
- 1980-07-10 JP JP9332780A patent/JPS5729295A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5729295A (en) | 1982-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4435327A (en) | 3β,7β,15α-Trihydroxy-5-androsten-17-one, its 3,15-dipivalate, and their preparation | |
JPH0121759B2 (en) | ||
US7002028B2 (en) | 5-androsten-3β-ol steroid intermediates and processes for their preparation | |
FI72729C (en) | Process for the preparation of novel therapeutically useful 6-methylhydrocortisone derivatives. | |
US4353985A (en) | Process for the preparation of 11 β-hydroxy steroids | |
JPH0120880B2 (en) | ||
JPS6137280B2 (en) | ||
US20070066579A1 (en) | 5-androsten-3beta-ol steroid intermediates and processs for their preparation | |
DD150223A5 (en) | PROCESS FOR THE PRODUCTION OF STEROIDS | |
EP0042451B1 (en) | Process for the preparation of 11-beta-hydroxy steroids | |
US6828120B2 (en) | Process to prepare 11β, 17α,21-trihydroxy-6α-methylpregna-1,4-diene-3,20-dione 21-acetate | |
US20060100185A1 (en) | 5-Androsten-3beta-ol steroid intermediates and processes for their preparation | |
DD150749A5 (en) | PROCESS FOR THE PREPARATION OF 11 BETA HYDROXYSTEROIDS OF THE PREGNANIUM SERIES | |
DE2901561A1 (en) | Antiinflammatory tri:hydroxy-4-pregnene-3,20-di:one derivs. prodn. - by microbiological hydroxylation of 11-desoxy-17,21-alkoxy: methylenedioxy cpds. with Curvularia spp. | |
EP0013405B1 (en) | Process for the preparation of 19-hydroxy steroids of the androstane and pregnane series | |
HU183154B (en) | Process for preparing 11beta-hydroxy-steroids | |
US3998701A (en) | Process for the preparation of 17-acyl esters of 17α, 21-dihydroxysteroids of the pregnane series and novel products | |
DD151947A5 (en) | PROCESS FOR PREPARING 11 BETA HYDROXYSTEROIDS | |
CS220330B2 (en) | Method of producing 11beta-hydroxysteroid | |
US4088537A (en) | Δ1 Dehydrogenation of corticoids without side chain degradation by Septomyxa | |
JPS6361000B2 (en) | ||
JPS5926279B2 (en) | Pregnane-based 17-ester manufacturing method | |
JPH0120876B2 (en) | ||
CA1172590A (en) | Steroids of the pregnane series substituted in the 17- position, and their manufacture and use | |
EP1679317A2 (en) | 5-Androsten-3 -ol steroid intermediates and processes for fheir preparation |